• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Anuj Mahindra, M.D.


  • Saini N, Mahindra A.Novel immunomodulatory compounds in multiple myeloma.Expert Opin Investig Drugs. 2013 Feb;22(2):207-15.
  • Mahindra A, Pozzi S, Raje N.Clinical trials of bisphosphonates in multiple myeloma.Clin Adv Hematol Oncol. 2012 Sep;10(9):582-7.
  • Mahindra A, Anderson KC.Role of Interleukin 16 in Multiple Myeloma Pathogenesis: * A Potential Novel Therapeutic Target?.Journal of the National Cancer Institute. 2012 Jun 28.
  • Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K.Latest advances and current challenges in the treatment of multiple myeloma.Nat Rev Clin Oncol. 2012 Feb 21.
  • Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P.Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.Leukemia. 2011 Nov 1.
  • Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).Eur J Haematol. 2011 Oct 12.
  • Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.Management of relapsed and relapsed/refractory multiple myeloma.J Natl Compr Canc Netw. 2011 Oct;9(10):1209-16.
  • Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E.Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.Bone Marrow Transplant. 2011 Apr 4.
  • Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide.Clin Cancer Res. 2011 Mar 23.
  • Mahindra A, Hideshima T, Anderson KC.Multiple myeloma: biology of the disease.Blood Rev. 2010 Nov;24 Suppl 1:S5-11.
  • Weaver J, Mahindra AK, Pohlman B, Jin T, Hsi ED.Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.J Cutan Pathol. 2010 May;37(5):516-24.
  • Mahindra A, Cirstea D, Raje N.Novel therapeutic targets for multiple myeloma.Future Oncol. 2010 Mar;6(3):407-18. Review.
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
  • Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia. 2009 Dec;23(12):2222-32. Review.
  • Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Kalaycio M, Sweetenham J, Bolwell B, Copelan E.Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation.Bone Marrow Transplant. 2009 Dec;44(11):767-8.
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
  • Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation.British Journal of Haematology. 2009 Aug;146(3):310-6.
  • Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.Biol Blood Marrow Transplant. 2008 Nov;14(11):1239-44.
  • Kalmadi S, Baz R, Mahindra A.Lenalidomide: the emerging role of a novel targeted agent in malignancies.Drugs Today. 2007 Feb;43(2):85-95. Review.
  • Mahindra AK, Grossman SA.Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.J. Neurooncol. 2003 Jul;63(3):263-70.